- Home
- TLS vs AVIR Comparison
TLS vs AVIR Comparison
Compare TLS & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLS
- AVIR
- Stock Information
- Founded
- TLS 1969
- AVIR 2012
- Country
- TLS United States
- AVIR United States
- Employees
- TLS N/A
- AVIR N/A
- Industry
- TLS EDP Services
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- TLS Technology
- AVIR Health Care
- Exchange
- TLS Nasdaq
- AVIR Nasdaq
- Market Cap
- TLS 249.6M
- AVIR 247.5M
- IPO Year
- TLS 2020
- AVIR 2020
- Fundamental
- Price
- TLS $3.47
- AVIR $3.29
- Analyst Decision
- TLS Buy
- AVIR Hold
- Analyst Count
- TLS 5
- AVIR 1
- Target Price
- TLS $4.50
- AVIR $6.88
- AVG Volume (30 Days)
- TLS 324.5K
- AVIR 510.6K
- Earning Date
- TLS 11-12-2024
- AVIR 11-07-2024
- Dividend Yield
- TLS N/A
- AVIR N/A
- EPS Growth
- TLS N/A
- AVIR N/A
- EPS
- TLS N/A
- AVIR N/A
- Revenue
- TLS $122,959,000.00
- AVIR N/A
- Revenue This Year
- TLS N/A
- AVIR N/A
- Revenue Next Year
- TLS $38.31
- AVIR N/A
- P/E Ratio
- TLS N/A
- AVIR N/A
- Revenue Growth
- TLS N/A
- AVIR N/A
- 52 Week Low
- TLS $1.89
- AVIR $2.75
- 52 Week High
- TLS $5.03
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- TLS 48.64
- AVIR 55.51
- Support Level
- TLS $3.26
- AVIR $3.10
- Resistance Level
- TLS $3.91
- AVIR $3.32
- Average True Range (ATR)
- TLS 0.22
- AVIR 0.14
- MACD
- TLS -0.00
- AVIR 0.04
- Stochastic Oscillator
- TLS 33.33
- AVIR 95.58
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).